Galena Biopharma Inc. (NASDAQ:GALE) is subject of the U.S. Securities Exchange Commission investigations. The biotech is facing claims of authorizing unlawful marketing campaigns that created a buzz in the stock and inflated shares, allowing insiders to make millions of dollars through the sale of thousands of shares. Galena Biopharma Inc. (NASDAQ:GALE) shares after opening at $1.89 moved to $1.90 on last trade day and at the end of the day closed at $1.80. Company price to sales ratio in past twelve months was calculated as 84.88 and price to cash ratio as 4.44. Galena Biopharma Inc. (NASDAQ:GALE) showed a negative weekly performance of -16.67%.
One stock that might be an intriguing choice for investors right now is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). This is because this security in the Medical-Drugs industry space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares ended the day on $3.20. RIGL return on equity ratio is recorded as -37.80% and its return on assets is -35.30%. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) yearly performance is -31.91%.
TherapeuticsMD (NYSEMKT:TXMD) had its target price lifted by Noble Financial from $9.00 to $13.00 in a research note released on Thursday morning, Stock Ratings Network reports. They currently have a buy rating on the stock. TherapeuticsMD Inc. (NYSEMKT:TXMD) shares moved up 4.48% in last trading session and was closed at $4.90, while trading in range of $4.58 – $5.00. TherapeuticsMD Inc. (NYSEMKT:TXMD) year to date (YTD) performance is -5.95%.
Several analysts have recently commented on the stock. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Arrowhead Research Corp (NASDAQ:ARWR) in a research note on Monday, March 24th. Arrowhead Research Corp (NASDAQ:ARWR) weekly performance is -19.53%. On last trading day company shares ended up $12.77. Arrowhead Research Corp (NASDAQ:ARWR) distance from 50-day simple moving average (SMA50) is -34.24%. Analysts mean target price for the company is $28.75.